RhythmAnalytics vs EchoNext

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 75/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

RhythmAnalytics

by Biofourmis Singapore Pte.

EchoNext

by Pathway Labs

AI Verdict

Both RhythmAnalytics and EchoNext are FDA-cleared AI tools for cardiology, offering clinical decision support based on ECG analysis. RhythmAnalytics focuses on the automated interpretation and detection of various cardiac arrhythmias from single-lead ECG data, while EchoNext analyzes standard ECGs to detect hidden structural heart diseases like heart failure, valve disease, and pulmonary hypertension. Therefore, RhythmAnalytics is more suited for rhythm disorder analysis, whereas EchoNext excels in identifying underlying structural heart conditions.

Choose RhythmAnalytics if…

Choose RhythmAnalytics if your primary need is automated, highly accurate interpretation of cardiac arrhythmias from single-lead ECG data, particularly for continuous or ambulatory monitoring. This tool is ideal for healthcare professionals and integrators who require clinical decision support for detecting over 15 types of cardiac arrhythmias, including AFib and ventricular arrhythmias, from various FDA-cleared ECG devices and wearable sensors. It excels in transforming labor-intensive rhythm classification into a high-yield diagnostic process.

View RhythmAnalytics →

Choose EchoNext if…

Choose EchoNext if your focus is on detecting hidden structural heart disease, such as heart failure, valve disease, and pulmonary hypertension, from standard 12-lead ECGs. This tool is best suited for broad screening in various clinical settings, from major hospitals to community practices, to identify patients who may require further diagnostic imaging like echocardiograms. It offers a non-invasive approach to identify high-risk conditions that might otherwise be missed by traditional ECG interpretation.

View EchoNext →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	RhythmAnalytics	EchoNext
Pricing	Contact vendor	Starts at $600/month
Deployment	Cloud-based API	Available through the OpenEvidence clinical decision support platform.
BAA Available	Unknown	Yes AI-estimated
FDA Status	1 AI-estimated	Yes AI-estimated
HIPAA	Unknown	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

EchoNext

EchoNext is available through the OpenEvidence clinical decision support platform, which is used by a significant number of U.S. physicians, suggesting a streamlined integration into existing clinical workflows. RhythmAnalytics is a cloud-based API that requires integration into existing cardiac monitoring solutions or medical devices, which may involve more setup and development work for end-users.

Clinical Value

EchoNext

EchoNext detects hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension, from standard ECGs, a capability traditionally not possible with ECGs alone. Studies show EchoNext outperforms cardiologists in identifying structural heart problems. RhythmAnalytics focuses on automated interpretation of cardiac arrhythmias, which, while valuable, addresses a different and more established diagnostic area.

Pricing & Value

EchoNext

EchoNext offers transparent tiered pricing starting at $600/month, with details on different plans, implementation fees, and discounts. RhythmAnalytics' pricing is 'contact vendor,' which offers less transparency for potential buyers. While both offer significant clinical value, EchoNext's clear pricing structure provides a better understanding of the investment required.

Enterprise Readiness

EchoNext

EchoNext is designed for broad access, from major hospitals to community practices, and has partnered with OpenEvidence, a platform used by a large number of U.S. clinicians, indicating strong enterprise deployment capabilities. RhythmAnalytics is a cloud-based API compatible with FDA-cleared ECG devices, suggesting good integration potential, but its enterprise readiness is less explicitly detailed beyond API integration.

Innovation

EchoNext

EchoNext represents a significant innovation by enabling the detection of hidden structural heart disease from standard ECGs, a capability previously requiring more expensive and less accessible tests like echocardiography. This expands the utility of a common, inexpensive test. RhythmAnalytics offers advanced AI-powered arrhythmia interpretation, which is an enhancement of existing ECG analysis, but EchoNext's ability to detect structural heart disease from ECGs is a more novel diagnostic breakthrough.

Support & Docs

Tie

Neither the provided structured facts nor the web search results offer specific details regarding the level of customer support, training, or comprehensive documentation available for either RhythmAnalytics or EchoNext. Therefore, it is not possible to definitively pick a winner in this dimension.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	RhythmAnalytics	EchoNext
Tool Name	RhythmAnalytics	EchoNext
Company	Biofourmis Singapore Pte.	Pathway Labs
Description	FDA-cleared, AI-powered cloud-based software that provides automated interpretation of cardiac arrhythmias from single-lead ECG data, offering clinical decision support for healthcare professionals and integrators.	FDA-cleared AI tool that analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension.
Key Detections	Over 15 types of cardiac arrhythmias (including AFib, ventricular arrhythmias, ectopic beats), beat-by-beat morphology computation, QRS and Ventricular Ectopic Beat detection, QRS feature extraction, interval measurement, heart rate measurement, and rhythm analysis.	Hidden structural heart disease, heart failure risk, valve disease, pulmonary hypertension indicators.
ECG Input Type	Single-lead ECG data (compatible with FDA-cleared ECG devices like Holter, event recorders, wearable sensors)	Standard 12-lead ECGs

Videos

Demos, reviews, and walkthroughs featuring RhythmAnalytics and EchoNext.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into existing clinical workflows and EHR systems?

RhythmAnalytics offers a cloud-based API for integration into existing cardiac monitoring solutions or directly into medical devices and wearable sensors. EchoNext is available through the OpenEvidence clinical decision support platform, which aims to put the screening output in front of physicians using tools they already utilize at the point of care.

What is the accuracy and sensitivity of each tool in detecting their respective cardiac conditions?

RhythmAnalytics demonstrated a sensitivity of 90.8% and specificity of 98.2% for arrhythmia detection, outperforming a panel of cardiologists. EchoNext accurately identified 77% of structural heart problems in a head-to-head comparison with 13 cardiologists on 3,200 ECGs, where cardiologists had an accuracy of 64%.

Given their specialized focus, which tool is a better fit for a general cardiology practice versus a more specialized setting?

RhythmAnalytics is designed for automated interpretation of cardiac arrhythmias from single-lead ECG data, detecting over 15 types of arrhythmias, making it suitable for general cardiology and emergency medicine. EchoNext analyzes standard 12-lead ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension, which could be valuable for both general and specialized cardiology practices to screen for conditions that might otherwise be missed.

What is the typical learning curve for physicians to effectively utilize these AI tools in their practice?

While specific learning curve data isn't provided for either tool, EchoNext is designed to analyze ECG data to identify patients who should be evaluated for structural heart disease, essentially 'seeing' patterns a cardiologist might miss, suggesting it augments existing interpretation rather than requiring extensive new diagnostic skills. RhythmAnalytics provides automated interpretation and clinical decision support, aiming to improve accuracy and scalability of ECG analysis, which could streamline existing workflows.

What kind of customer support and resources are available to assist with implementation and ongoing use?

Biofourmis, the company behind RhythmAnalytics, works with leading hospitals like Mayo Clinic and Brigham and Women's Hospital, suggesting established support structures. Pathway Labs, the developer of EchoNext, has partnered with OpenEvidence to expand access to the screening tool, indicating a focus on broader physician adoption and presumably associated support.

Can these tools provide audit trails or detailed logs of their analysis for review and accountability?

While explicit audit trail features are not detailed for RhythmAnalytics, its function as clinical decision support for healthcare professionals implies a need for review and confirmation of analytic results. For EchoNext, the model's ability to identify high-risk patients for follow-up echocardiograms suggests a traceable output that guides further diagnostic steps.

How do these tools handle multi-site or large-scale rollouts, and what considerations are there for consistent performance?

RhythmAnalytics is a cloud-based API, which inherently supports scalability and integration into various cardiac monitoring solutions. EchoNext has demonstrated consistent performance across diverse patient demographics, clinical contexts, and numerous hospitals in validation studies, and its partnership with OpenEvidence aims for broad access across major hospitals to community practices.